RecruitingNCT05918510

Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus


Sponsor

Regina Elena Cancer Institute

Enrollment

142 participants

Start Date

Apr 4, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids of these patients, may have important prognostic and diagnostic value not only in HPV-related OPSCCs but also in HPV+ occult T. Accordingly, this study aims to aim to better characterize their potential as biomarkers and to detect the possibility of their their use to implement the sensitivity and specificity of radiological methodologies (PET-CT and MRI), already in use in clinical practice, for monitoring disease progression in this specific subgroup. Finally, by using the collected material to generate organoids and Patient Derived Xenograft (PDX), the study also aims to identify possible new molecular drugs, which could solve the problem of resistance to radiochemotherapy.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Squamous cell carcinomas of the oropharynx and occult neoplasms with lymph node metastases laterocervical cytologically positive for squamous cell carcinoma treated with TORS or RT or RT/CT
  • Age \> 18 years
  • ECOG performance status \<\_ 2
  • Ability to follow study procedures and complete questionnaires
  • Signature of informed consent

Exclusion Criteria3

  • Presence of distant metastases at the time of diagnosis
  • Previous cancer of the head and neck district
  • Second tumor in therapy or follow-up for less than 5 years

Interventions

DIAGNOSTIC_TESTStudy of Viral BIOmarkers and microRNAs in Tumors Orofarynx

The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.


Locations(1)

"Regina Elena" National Cancer Institute

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05918510


Related Trials